Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,accountsPayable,deferredLongTermLiab,otherCurrentLiab,otherLiab,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,currency,priceHint,shortName,exchange,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,exchangeDataDelayedBy,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,marketState,postMarketChangePercent,postMarketTime,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,market,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,GBIO,458736000.0,56633600,16533000,,-25562000,,-25562000,9122000,0,-25655000,-25655000,,,,,,0,0,25655000,0,93000,,-25562000,-25562000,673257000.0,55345000.0,458736000.0,514081000.0,6000.0,-214537000.0,10000.0,2388000.0,366304000.0,10794000.0,10000.0,55908000.0,455785000.0,84779000.0,296000.0,,,,114400000,-145000,113485000,212957000,-2123000,213395000,303415000,-23027000,1064000,-438000,3739000,-915000,444991000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,25.67,1630526402,0.6700001,25.09,26.22,24.74,175865,-3.0497818,-0.10619098,1453784576,15,America/New_York,EDT,-14400000,False,False,USD,2,Generation Bio Co.,NMS,-2.18,-11.775229,22.526667,3.1433334,0.13953833,28.719782,0,finmb_548482897,NasdaqGS,Generation Bio Co.,USD,338156,350950,6.5149994,0.34012002,19.155 - 55.72,-30.050001,-0.53930366,19.155,55.72,1620836400,1628506740,1628856000,POST,0.0,1630526421,25.67,0.0,2.6800003,24.74 - 26.22,25.0,23.77,27.31,30,9,us_market,,,,55.72,19.16,22.53,28.72,338.16k,350.95k,56.63M,,36.46M,8.69%,97.60%,4.4M,15.8,14.70%,7.77%,4.54M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-17.15%,-31.09%,,,,,-84.91M,-88.37M,,,451.08M,8.03,48.77M,10.63,42.23,,-75.39M,-48.07M,Value,02142,Healthcare,100,8,8,"Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 655 7500,MA,8,1609372800,1622505600,10,United States,http://generationbio.com,86400,9,301 Binney Street,Biotechnology
t-1,GBIO,268013000.0,56633600,14079000,,-24226000,,-24226000,10266000,0,-24345000,-24345000,,,,,,0,0,24345000,0,119000,,-24226000,-24226000,456974000.0,26142000.0,268013000.0,294155000.0,5000.0,-188975000.0,9000.0,2639000.0,62889000.0,11220000.0,9000.0,23781000.0,267735000.0,199438000.0,267000.0,336000.0,1389000.0,14922000.0,22145000,-123000,20351000,2297000,1453000,2338000,4283000,-18365000,991000,-41000,3540000,-1794000,256515000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,25.67,1630526402,0.6700001,25.09,26.22,24.74,175865,-3.0497818,-0.10619098,1453784576,15,America/New_York,EDT,-14400000,False,False,USD,2,Generation Bio Co.,NMS,-2.18,-11.775229,22.526667,3.1433334,0.13953833,28.719782,0,finmb_548482897,NasdaqGS,Generation Bio Co.,USD,338156,350950,6.5149994,0.34012002,19.155 - 55.72,-30.050001,-0.53930366,19.155,55.72,1620836400,1628506740,1628856000,POST,0.0,1630526421,25.67,0.0,2.6800003,24.74 - 26.22,25.0,23.77,27.31,30,9,us_market,,,,55.72,19.16,22.53,28.72,338.16k,350.95k,56.63M,,36.46M,8.69%,97.60%,4.4M,15.8,14.70%,7.77%,4.54M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-17.15%,-31.09%,,,,,-84.91M,-88.37M,,,451.08M,8.03,48.77M,10.63,42.23,,-75.39M,-48.07M,Value,02142,Healthcare,100,8,8,"Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 655 7500,MA,8,1609372800,1622505600,10,United States,http://generationbio.com,86400,9,301 Binney Street,Biotechnology
t-2,GBIO,286539000.0,56633600,12953000,,-20849000,,-20849000,8016000,0,-20969000,-20969000,,,,,,0,0,20969000,0,120000,,-20849000,-20849000,451257000.0,24383000.0,286539000.0,310922000.0,5000.0,-164749000.0,26000.0,2221000.0,58605000.0,9163000.0,26000.0,22888000.0,285813000.0,221761000.0,418000.0,,2020000.0,15220000.0,-92424000,-2120000,-93925000,-648000,1268000,1044000,-113086000,-18513000,939000,-1692000,2249000,-1501000,276650000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,25.67,1630526402,0.6700001,25.09,26.22,24.74,175865,-3.0497818,-0.10619098,1453784576,15,America/New_York,EDT,-14400000,False,False,USD,2,Generation Bio Co.,NMS,-2.18,-11.775229,22.526667,3.1433334,0.13953833,28.719782,0,finmb_548482897,NasdaqGS,Generation Bio Co.,USD,338156,350950,6.5149994,0.34012002,19.155 - 55.72,-30.050001,-0.53930366,19.155,55.72,1620836400,1628506740,1628856000,POST,0.0,1630526421,25.67,0.0,2.6800003,24.74 - 26.22,25.0,23.77,27.31,30,9,us_market,,,,55.72,19.16,22.53,28.72,338.16k,350.95k,56.63M,,36.46M,8.69%,97.60%,4.4M,15.8,14.70%,7.77%,4.54M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-17.15%,-31.09%,,,,,-84.91M,-88.37M,,,451.08M,8.03,48.77M,10.63,42.23,,-75.39M,-48.07M,Value,02142,Healthcare,100,8,8,"Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 655 7500,MA,8,1609372800,1622505600,10,United States,http://generationbio.com,86400,9,301 Binney Street,Biotechnology
t-3,GBIO,304153000.0,56633600,11148000,,-17731000,,-17731000,6616000,0,-17764000,-17764000,,,,,,0,0,17764000,0,33000,,-17731000,-17731000,448052000.0,27049000.0,304153000.0,331202000.0,5000.0,-143900000.0,-4000.0,2203000.0,171691000.0,11536000.0,-4000.0,22822000.0,306177000.0,129395000.0,2624000.0,,2373000.0,15513000.0,-129399000,2103000,-129611000,212313000,-2049000,213931000,67218000,-15484000,825000,-1428000,1368000,-212000,294641000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,25.67,1630526402,0.6700001,25.09,26.22,24.74,175865,-3.0497818,-0.10619098,1453784576,15,America/New_York,EDT,-14400000,False,False,USD,2,Generation Bio Co.,NMS,-2.18,-11.775229,22.526667,3.1433334,0.13953833,28.719782,0,finmb_548482897,NasdaqGS,Generation Bio Co.,USD,338156,350950,6.5149994,0.34012002,19.155 - 55.72,-30.050001,-0.53930366,19.155,55.72,1620836400,1628506740,1628856000,POST,0.0,1630526421,25.67,0.0,2.6800003,24.74 - 26.22,25.0,23.77,27.31,30,9,us_market,,,,55.72,19.16,22.53,28.72,338.16k,350.95k,56.63M,,36.46M,8.69%,97.60%,4.4M,15.8,14.70%,7.77%,4.54M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-17.15%,-31.09%,,,,,-84.91M,-88.37M,,,451.08M,8.03,48.77M,10.63,42.23,,-75.39M,-48.07M,Value,02142,Healthcare,100,8,8,"Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 655 7500,MA,8,1609372800,1622505600,10,United States,http://generationbio.com,86400,9,301 Binney Street,Biotechnology
